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Abstract
Background: The hypomethylating agent 5-Azacytidine (5-Aza-CR) is the first drug to prolong overall survival in patients
with myelodysplastic syndrome (MDS). Surprisingly, the deoxyribonucleoside analog 5-Aza-29deoxycytidine (5-Aza-CdR) did
not have a similar effect on survival in a large clinical trial. Both drugs are thought to exert their effects after incorporation
into DNA by covalent binding of DNA methyltransferase (DNMT). While 5-Aza-CdR is incorporated into only DNA, 5-Aza-CR
is also incorporated into RNA. Here, we have analyzed whether this difference in nucleic acid incorporation may influence
the capacities of these drugs to regulate the expression of mRNA and microRNAs (miRNA), which may potentially affect the
activities of the drugs in patients.
Methodology/Principal Findings: A hematopoietic (HL-60; acute myeloid leukemia) and a solid (T24; transitional cell
carcinoma) cancer cell line were treated with equitoxic doses of 5-Aza-CR and 5-Aza-CdR for 24 hrs, and the immediate (day
2) and lasting (day 8) effects on RNA expression examined. There was considerable overlap between the RNAs heritably
upregulated by both drugs on day 8 but more RNAs were stably induced by the deoxy analog. Both drugs strongly induced
expression of cancer testis antigens. On day 2 more RNAs were downregulated by 5-Aza-CR, particularly at higher doses. A
remarkable downregulation of miRNAs and a significant upregulation of tRNA synthetases and other genes involved in
amino acid metabolism was observed in T24 cells.
Conclusions/Significance: Overall, this suggests that significant differences exist in the immediate action of the two drugs,
however the dominant pattern of the lasting, and possible heritable changes, is overlapping.
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Introduction
The nucleoside analogs 5-Azacytidine (5-Aza-CR) and 5-Aza-
29-deoxycytidine (5-Aza-CdR) both have profound effects on the
differentiated state of cultured cells [1]. It is generally assumed that
this activity is related to the abilities of both drugs with an
azanucleoside ring to be incorporated into replicating DNA,
resulting in a powerful inhibition of DNA methyltransferases [2].
While 5-Aza-CdR is incorporated through a direct route into
DNA, the ribose analog 5-Aza-CR must first be reduced at the
diphosphate level by ribonucleotide reductase in order to be
incorporated into DNA and hence inhibit DNA methylation.
However a considerable portion of the drug can be incorporated
into RNA where it could presumably influence RNA synthesis and
metabolism. Nevertheless, the fact that both compounds are only
active in the S phase of the cell cycle does imply a DNA linked
mechanism of action [3].
Both drugs are approved by the US Food and Drug
Administration (FDA) for the treatment of myelodysplastic
syndrome (MDS), which is a malignant disease of the myeloid
stem cells that primarily affects elderly patients. Hitherto, only
high-dose myeloablative chemotherapy and allogeneic hemato-
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MDS patients, however this regimen is only feasible in the smaller
fraction of younger MDS patients. Over the last decade clinical
trials have established the efficacies of both drugs in causing
disease remission in MDS and acute myeloid leukemia (AML)
[4,5,6,7,8,9], however two recent phase III clinical trials have
shown that while 5-Aza-CR gave a distinct overall survival
advantage to high risk MDS patients when compared to
conventional care regimens [10], this was not seen in a trial
conducted with the deoxy analog [11]. There are many potential
reasons for this discrepancy, not the least of which is the different
route of administration of the drugs, a different number of
treatment cycles, and patient selection as demonstrated by
differences in survival rates also in the control arms (15 months
in the 5-Aza-CR study vs. 8,5 months in the 5-Aza-CdR study,
respectively). Nonetheless, the result is surprising since both drugs
do cause substantial decreases in DNA methylation, which is
clearly associated with gene activation.
One remarkable difference between the two drugs is that 5-Aza-
CR is incorporated into RNA in addition to its DNA related
effects. The possibility therefore exists that this potential
interference with RNA structure and function might be associated
with different activities of the drugs in patients. We have therefore
used high-throughput screening approaches to examine the effects
of the drugs on mRNA and miRNA expression in an AML cell
line (HL-60) and a solid tumor cell line (T24) at equitoxic doses of
the drugs. We conducted our analyses at two time-points to detect
immediate effects of the drugs on RNA expression and then
repeated the analysis seven days after the drug had been removed
from treated cells to compare and contrast heritable changes in
gene expression induced by the two azanucleosides. The data
show early changes in RNA synthesis, which might be due to RNA
incorporation of the ribo analog yet clearly demonstrate the
increased number of genes induced heritably by the deoxy analog
5-Aza-CdR.
Materials and Methods
Cell lines
The HL-60 cell line was originally derived from a female patient
with AML-FAB M2 [12]. Its origin was confirmed by M-FISH
(supplementary Fig. S1). The T24 cell line was derived from a
female patient with urinary bladder transitional cell carcinoma. Its
origin was confirmed by tandem repeat analysis (data not shown).
HL-60 cells were cultured in RPMI 1640 medium with Glutamax-
1 plus 10% FBS. T24 cells were cultured in McCoy’s 5A medium
supplemented with 10% FBS. To both cultures 100 units/ml
penicillin and 100 mg/ml streptomycin was added.
Drug treatment and determination of cell doubling
times, cell cycling and apoptosis
To determine the optimal drug doses, HL-60 cells and T24 cells
were treated with increasing concentrations of 5-Aza-CR or 5-Aza-
CdR (Sigma-Aldrich, St. Louis, MO) for 24 h, the medium was
changed, and cells were counted every 2 to 3 days with a
Hemacytometer (Hausser Scientific, Horsham, PA) or a Z1 Coulter
Particle Counter (Beckman Coulter Corporation, Hialeah, FL) and
harvested on day 8. The equitoxic doses that led to approximately
50% prolongation in doubling time as compared to untreated cells
were chosen for the microarray experiments. Apoptosis (Annexin
V/FITC and Propidium Iodide) (BD Pharmingen, Franklin Lakes,
NJ) and cell cycle analysis (EDU/7-AAD) assays (Invitrogen,
Carlsbad, CA) were done to evaluate the effects of the drugs on
apoptosis and cell cycling on day 2 and 8.
The cell cultures and drug doses used for subsequent microarray
analysis were as follows: HL-60 cells were seeded at 5610
5 cells/
25 cm
2 flask (1610
5 cells/ml) 24 hrs prior to treatments and
treated with 0.5 mM 5-Aza-CR or 0.1 mM 5-Aza-CdR (Sigma-
Aldrich, St. Louis, MO). T24 Cells were plated at 3610
5 cells/
100-mm dish and treated the next day with 30 mM 5-Aza-CR or
1 mM 5-Aza-CdR (Sigma-Aldrich, St. Louis, MO). The medium
was changed after 24 hrs treatment, and cells were collected 1 day
and 7 days after the drug had been removed. The cell number/
flask or dish was counted every 2 to 3 days. Untreated cells were
grown under similar conditions as a control. Two independent
experiments were performed for each cell line.
Nucleic acid extraction
Genomic DNA was collected with DNeasy Tissue Kit (Qiagen,
Valencia, CA) according to the manufacturer’s protocol. RNA was
extracted using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions.
Microarray analysis
A total number of 24 mRNA arrays and 13 miRNA arrays were
analyzed. All mRNA arrays were run in biological and technical
duplicates at each time point i.e. the following samples were
analyzed: Six T24 samples (day 2: untreated/5-Aza-CR treated/5-
Aza-CdR treated, and day 8: untreated/5-Aza-CR treated/5-Aza-
CdR treated) and six HL-60 samples (day 2: untreated/5-Aza-CR
treated/5-Aza-CdR treated, and day 8: untreated/5-Aza-CR
treated/5-Aza-CdR treated). MiRNA arrays were analyzed in
the same setup but in singlicate, (except for T24 on day 2 which
was done in duplicate). Each miRNA-array contains 4 copies of
each probe. All array data is MIAME compliant and the raw data
has been deposited in ArrayExpress, (accession number E-MTAB-
279/280).
Labeling and processing of mRNA data. Total RNA was
labeled and hybridized to Illumina HG6 v3 beadarrays (Illumina,
San Diego, CA) according to manufactures protocol. Two technical
replicates were performed for each time point. Unnormalized
summary data was exported from BeadStudio (Illumina, San Diego,
CA) and imported into R/bioconductor using the BeadArray
package, normalized using qspline [13] and batch corrected using a
proprietary SVD correction. Data were annotated using http://
www.compbio.group.cam.ac.uk/Resources/Annotation [14].
Probes designated as ‘‘Bad’’ were eliminated from further analysis.
Labeling and processing of microRNA. RNA was labeled
according to manufactures protocol using miRCURY LNA
TM
microRNA Hy3/Hy5 Power labeling kit (Exiqon, Hørsholm,
Denmark). RNA from HL-60/T24 was labeled with Hy3 and a
mix of all samples was used as a common reference and labeled
with Hy5. Five hundred ng of total RNA was hybridized on
miRCURY LNA
TM microRNA Array (Exiqon, Hørsholm,
Denmark), v.11.0 using a Tecan HS4800 PRO (Tecan,
Ma ¨nnedorf, Switzerland). Arrays were scanned on an Agilent
scanner G2565CA (Agilent technologies, Santa Clara, CA) at
5 mm and 16 bit settings. Feature extraction was performed using
GenePix Pro 6.1 (Molecular devices, Sunnyvale, CA) and
Morphological background subtraction. Intensity values were
imported into R 2.9.2 and analyzed using Limma [15]. The
Lowess algorithm was used to normalize the expression values,
and normalization between arrays was performed using Aquantile.
Detection of differential expression. Differential expression
analysis was done using Limma [15]. First by fitting a linear model
of the data to experimental design matrix and then by calculating
Bayesian statistics. P-values were adjusted using the Benjamini-
Hochberg correction.
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replicates were collapsed into one using Limmas linear fit. Log 2
transformed expression values were annotated with HUGO
symbols. These data were imported into javaGSEA desktop
application v 2.0 [16,17] where they were analyzed using 1000
permutations based on gene set, and signal2noise for ranking.
Results were interpreted as positive if FDR corrected P-values
were ,0.05.
Methylation-specific single nucleotide primer extension
(Ms-SNuPE)
Two mg of each DNA sample was converted with EpiTect
Bisulfite Kit (Qiagen, Valencia, CA) according to the manufac-
turer’s protocol and each region of interest was amplified by PCR.
The bisulfite specific PCR primer sequences for the XAGE1D
promoter are as follows sense 59-TTATATATAGAGAGGAGG-
GATTTT-39 and antisense 59-AACTCCCAATTAAATCTAC-
CTA-39. PCR conditions were as follow: 95uC for 5 min, followed
by 95uC for 1 min, 55uC; 1 min, 72uC; 1 min, for a total of 40
cycles. The PCR amplicons were extracted with the Gel
Extraction Kit (Qiagen, Valencia, CA), and Ms-SNuPE analysis
was performed to examine the methylation level changes as
previously described [18]. Primers used for Ms-SNuPE analysis
were 59-TTTTTTGGTGTTTATTTTAGTG-39 and 59-
GTTAGTGTGGGGAA-39. PCR conditions: One cycle of 95uC
for 1 min, 50uC for 1 min, 72uC for 1 min.
Methylation specific melting curve analysis (Ms-MCA)
For methylation screening of the candidate tumor suppressor
gene (TSG) BTG2 we used Ms-MCA as described [19].
Amplification was carried out on a LightCycler 480 instrument
(Roche diagnostics, Basel, Switzerland) using the Fast Start SYBR
green I Kit (Roche diagnostics, Basel, Switzerland), sense primer
59- GGGTAAgGTTGTTTTGTGGATT-39 and anti-sense prim-
er 59-TTTTTATTcGAGATTTTTTATTGAGTT. The PCR
conditions were as follows: 5 min of initial enzyme activation at
95uC, 45 cycles of denaturation at 95uC for 10 s, annealing at
60uC for 20 s and elongation 72uC for 30 s. Subsequently, melting
curves were obtained by measuring the drop in fluorescence when
raising the temperature from 67 to 98uC with 5 observations per
second. The melting peaks were calculated using the LightCycler
480 Software Release 1.5.0SP3.
Quantitative real-time PCR
Reverse transcription (RT) was performed with M-MLV reverse
transcriptase and random hexamers (Promega, Madison, WI)
according to the manufacturer’s instructions. Quantitative real-
time PCR for XAGE1D was done using TaqMan probes
(Biosearch Technologies, Novato, CA): sense primer 59-TCCCC-
AGACGGGACCAG-39 and antisense primer 59- CTGGCT-
GTGTGGTTCTGTGTTT -39, probe 59- FAM-AGAGG-
GACGGCATGAGCGACACAC-BHQ-39. The real-time RT-
PCR conditions were as follows: 95uC for 9 min, followed by 45
cycles of 95uC for 15 s and 60uC for 1 min. Confirmatory RT-
qPCR analysis of other CTAs and tumor suppressors was done on
the Light Cycler. For primers and conditions see supplementary
Table S1.
Results
The optimal doses of 5-Aza-CR and 5-Aza-CdR were
determined by monitoring the effects of increasing doses of both
compounds on the doubling times of the two cell lines (Fig. 1).
‘‘Equitoxic dose’’ was defined as the dose of both drugs leading to
similar doubling time changes and doses were picked that
increased the doubling time by approximately 50%. The two cell
lines showed considerable differences in drug sensitivity, in favor of
the myeloid cell line. The doses were 0.5 mM 5-Aza-CR and
0.1 mM 5-Aza-CdR for the HL-60 cells and 30 mM 5-Aza-CR and
1 mM 5-Aza-CdR for the T24 cells. At the chosen doses, no
Figure 1. Estimation of population doubling times in the HL-60 and the T24 cell lines. Population doubling (PD) curves of the HL-60 (a)
and (b) T24 cell line. Levels of cellular growth after treatment, with the indicated drug regimens plotted as population doublings against time. Initial
drug treatment was started 24 h after seeding. The lines are trend lines.
doi:10.1371/journal.pone.0012994.g001
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regards to the fraction of cells being in S-phase and apoptosis at
day 2 and 8 respectively. Notably, the high dose of 5-Aza-CR used
in the T24 cells did not cause increased apoptosis. In addition,
,20% apoptosis was observed in both cell lines at the chosen
doses at both time points (supplementary Fig. S2).
Changes in mRNA expression
Both drugs caused significant upregulation of a large number
of genes in the HL-60 cells on day 2 (Fig. 2). Although there was
a considerable overlap in the gene sets upregulated, 5-Aza-CdR
was clearly more effective at gene induction in that it induced
expression of 155 genes that did not overlap with genes
upregulated by the ribo analog. Neither drug caused substantial
downregulation of genes at the stringent cut off value (log2 fold
change .2). Interestingly, the overlap between the gene sets
increased on day 8, which is consistent with both drugs acting
predominantly through a heritable epigenetic process involving
DNA methylation. The fact that 5-Aza-CdR activated more
genes and that only 9 genes were exclusively upregulated by 5-
Aza-CR on day 8 again points to the same mechanism of action.
The few genes that were downregulated at day 8 were probably
influenced by a negative regulatory process due to the switching
on of a subset of the 214 genes heritably activated by 5-Aza-
CdR.
The small number of genes immediately downregulated on day
2 by 5-Aza-CR in the HL-60 cells suggested that little drug was
being incorporated into RNA, where it might influence the
stability and/or processing of mRNA. This situation was different
in T24 cells where 12 mRNAs were immediately downregulated
by the ribo- but not the deoxyribo analog (Fig. 2). These changes
were not permanent and largely disappeared on day 8. More genes
were upregulated at both time points exclusively by 5-Aza-CR in
the T24 cells than in the HL-60 cells. Overall the data show
considerable overlap of the gene sets heritably altered by both
drugs in both cell types with 5-Aza-CdR being the most effective.
On the other hand, the fact that a unique set of genes was altered
by the ribo analog in T24 cells on day 8 suggests that interference
with RNA metabolism during drug treatment can also induce
heritable effects on gene expression.
Common pathways upregulated by the two drugs
A more detailed GSEA of the mRNA expression data shows
that both drugs deregulate a set of genes, which are also
deregulated in Dnmt1 KO mouse cells [20] (see supplementary
Table S2). However, quite surprisingly, none of the TSGs known
Figure 2. mRNA expression after treatment with 5-Aza-CR and 5-Aza-CdR. Venn diagrams showing differentially expressed transcripts in
the HL-60 AML cell line and the T24 bladder cancer cell line harvested and analyzed 1 and 7 days after treatment with equitoxic doses of 5-Aza-CR
and 5-Aza-CdR. The numbers in each area show genes differentially expressed in treated relative to untreated cells. Upregulated genes are shown in
green, downregulated genes in red. Numbers of upregulated CTAs, and the percentage they comprise of the total number of upregulated genes, are
indicated in blue.
doi:10.1371/journal.pone.0012994.g002
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PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12994Figure 3. Expression of cancer testis antigens in azanucleoside treated and untreated HL-60 and T24 cell lines. Heatmaps showing
CTAs that vary across treatment conditions (SD.0.25). The heatmaps were generated from the 83 CTAs present on the arrays based on genes
selected from the CTpedia database http://www.cta.lncc.br/index.php. Genes that did not vary were removed, leaving 39 CTAs in HL-60 cells and 46
CTAs in T24 cells. The linear fits from the Limma analysis were used to generate heatmaps. Data were clustered based on Euclidian distance and each
row were normalized using z-score. CpG islands were identified using www.cpgislands.com with standard settings except for length .200 bp.
doi:10.1371/journal.pone.0012994.g003
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(HIC-1, CDH1 and ER) [21] or in the T24 cell line (CDNK2A [18]
and RUNX3 [22]) was upregulated to significant levels by either of
the drugs. So, although previous studies have shown that these
types of changes are detectable by PCR based methods, the level
of upregulation of these genes was not large enough to be detected
by the arrays.
Interestingly, TSGs that have not been found methylated in
AML showed significant upregulation by both drugs in HL-60
with the highest upregulation induced by 5-Aza-CdR (supple-
mentary Fig. S3). These include critical cell cycle regulating tumor
suppressors such as cyclin dependent kinase inhibitors CDKN1C
(p57) and the cell cycle and differentiation associated BTG2. Since
the candidate TSG BTG2 has not previously been analyzed for
promoter methylation in AML, we performed methylation
scanning by Ms-MCA, but saw no methylation, indicating that
different mechanisms may have caused upregulation of BTG2. It
has been known for sometime that 5-Aza-CdR can turn on
unmethylated genes in addition to methylated genes [23].
Cancer testis antigens. A notable proportion of the genes
commonly upregulated by both drugs in both cell lines belong to
the group of cancer testis antigens (CTA; Fig. 2). All but one CTA
upregulated by 5-Aza-CR were also upregulated by 5-Aza-CdR,
which also upregulated additional CTAs. These antigens were
upregulated in HL-60 cells by both drugs already on day 2, and
the level of expression increased on day 8 for 5-Aza-CR but
decreased for 5-Aza-CdR treated cells. Hardly any expression was
induced in T24 cells on day 2 by 5-Aza-CR and for both drugs the
level of expression was highest on day 8 (Fig. 3).
A proportion of CTA genes have CpG islands in their
promoters (Fig. 3), and they are likely to be upregulated by
promoter demethylation (Fig. 4). A detailed analysis of the
XAGE1D promoter showed that this promoter is 95%
hypermethylated in the untreated HL-60 cell line. A 40%
reduction of methylation was induced by both drugs, however
5-Aza-CdR caused approximately 5 times higher expression
than 5-Aza-CR at both time points. No significant increase in
expression from day 2 to day 8 was seen in this cell line. In T24
cells, 5-Aza-CdR also led to a higher expression level than did
5-Aza-CR. Hardly any expression was induced on day 2 by 5-
Aza-CR, and a higher expression level was achieved on day 8
for both drugs (Fig. 4). Similar results were obtained by detailed
RT-qPCR analyses of different CTAs (supplementary Fig. S4).
Since not all CTAs have a CpG island in their promoters, we
speculated whether other factors might have induced the high
expression of CTAs. Interestingly, the CTCF paralogue
CTCFL/BORIS, that can reactivate the transcription of other
CTAs [24], was also upregulated by both drugs in both cell
lines. This gene has CpG islands in 2 of its 3 promoters and 5-
Aza-CdR has previously been shown to strongly upregulate
transcription by mechanisms both dependent and independent
of DNA methylation [25]. In HL-60 cells CTCFL/BORIS
showed significant upregulation already on day 2, and its
expression coincided with CTA upregulation. CTCFL/BORIS
is believed to antagonize CTCF and in this cell line, CTCF was
downregulated at each time point by both drugs. Only a minor
fraction of the CTAs was upregulated by 5-Aza-CR on day 2
with no upregulation of CTCFL/BORIS in T24 cells. More
upregulation of both CTCFL/BORIS and other CTAs was
seen by 5-Aza-CdR. On day 8 both drugs showed high
upregulation of a large proportion of CTAs including
CTCFL/BORIS (Fig. 3).
Figure 4. Induction of expression of XAGE1D by 5-Aza-CR and 5-Aza-CdR. Upper: Schematic drawing of the XAGE1D promoter CpG island.
CpG sites analyzed by Ms-SNuPE are indicated by the arrows. Lower: Level of promoter methylation estimated by Ms-SNuPE relative to the level of
mRNA expression estimated by RT-qPCR at equitoxic doses of 5-Aza-CR and 5-Aza-CdR on day 2 and day 8 in the HL-60 and the T24 cells.
doi:10.1371/journal.pone.0012994.g004
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also showed that commonly regulated pathways involved in
inflammation and immune mechanisms dominate (supplementary
Table S2). These involve activation of genes implicated in cytokine
signaling including members of the interleukin-, interferon- and
TNF receptor families. The upregulation of these pathways was
seen by both drugs on both days in HL-60 cells but only on day 8 in
T24 cells. Taken together, the CTAs and immunomodulatory
pathways are commonly upregulated by both drugs, particularly on
day 8, indicating that the heritable changes in gene expression are
similar for the two drugs.
Diverse pathway regulation by the two drugs
Since not many differences were seen in the heritable changes in
gene expression, we wondered if a diverse expression pattern is
seen early after treatment as has been suggested by others [26].
The most striking difference between the two drugs was that 5-
Aza-CdR upregulated a large number of genes that are not
expressed after 5-Aza-CR treatment. Interestingly, GSEA shows
that several gene sets related to MYC, MYB and E2F oncogene
signaling are enriched by 5-Aza-CdR treatment on day 2 in both
cell lines, indicating an immediate activation of growth promoting
pathways by this drug (supplementary Table S2). However, since
we have demonstrated that growth is inhibited in both cell lines at
this point (Fig. 1 and supplementary Fig. S2) the upregulation may
be transient or compensatory and therefore biologically irrelevant.
Furthermore, particularly in T24 cells a few gene sets were
upregulated more by 5-Aza-CR than by 5-Aza-CdR as described
below.
Diverse pathways deregulated by the two drugs in the T24
cell line. One striking observation in T24 cells was that a large
number of tRNA synthetase genes (13/20=65% of all tRNA
synthetase genes) became upregulated to a significant level
(p,0.05) on day 2 by 5-Aza-CR but not by 5-Aza-CdR (Fig. 5).
This became even more pronounced when the cells were treated
with higher doses of 5-Aza-CR (50 mM) (data not shown). This
upregulation disappeared on day 8, where a general
downregulation of the tRNA synthetase genes was seen by both
drugs in both cell lines. Interestingly, GSEA showed that several
pathways associated with amino acid synthesis and metabolism
were deregulated on day 2 by 5-Aza-CR (supplementary Table
S2).
Effects of the two azanucleosides on miRNA expres-
sion. Since earlier results have shown that miRNAs are subject
to epigenetic control [27,28,29], it was essential to compare and
contrast the effects of the 2 drugs on miRNA expression. In
general, the altered expression patterns for miRNAs were different
from what was observed for mRNAs (Fig. 6).
On day two, 5-Aza-CR caused the most dramatic changes with
significant miRNA downregulation in both cell lines, which might
be a result of incorporation of the ribo analog into newly
synthesized miRNA molecules. In HL-60 cells 13 miRNAs were
down- and 14 upregulated, whereas in the T24 cell line as many as
46 miRNAs were down- and 9 upregulated immediately after
treatment. In contrast, the deoxyanalog (5-Aza-CdR) caused less
downregulation in both cell lines at this time point. In HL-60 cells
a similar number of miRNAs were upregulated by both drugs
while in T24 no miRNAs were upregulated by 5-Aza-CdR. This
immediate downregulatory response specific to the ribo analog
might reflect the incorporation of the drug directly into miRNAs
as they were being synthesized. On day 8 the pattern changed
radically: 5-Aza-CdR deregulated more miRNAs in both cell lines,
again indicating the higher potency of this drug to induce heritable
changes in expression.
Discussion
Within the last year Vidaza
TM (5-Aza-CR) has been shown to
prolong overall survival in MDS patients [10]. Accordingly, the
drug is now commonly used in high-risk MDS patients that are not
eligible for allogeneic stem cell transplantation. Since its
mechanisms of action are similar to the deoxy analog Dacogen
TM
(5-Aza-CdR) (see above), it was surprising that the two drugs
caused a different overall survival in the two recent phase III trials
in MDS patients [10,11]. To investigate whether this discrepancy
could also be associated with diverse biological actions of the two
drugs, involving possible RNA incorporation of 5-Aza-CR, we
have analyzed in detail the effects of azanucleosides on RNA
expression, and find that both coding and non-coding RNA
species are deregulated to a significant level by either drug (data
summarized in Table 1).
The main biological diversities between the two drugs are
observed on day 2 after treatment. At this time point, 5-Aza-CdR
upregulates a set of genes involved in oncogenic pathways,
however, the most striking finding is the immediate effect of 5-Aza-
CR on RNA metabolism, which was also recently shown by others
[30]. This may lead to early disruption of many pathways both via
the direct influence on protein synthesis, and indirectly via a
remarkable downregulation of miRNAs. The effect on RNA
metabolism seems to increase with higher doses of the drug.
Whether these early differences in RNA expression may also relate
to the variable success of treatment by the drugs in patients is
uncertain, given that the heritable changes may probably most
effectively maintain a clinical response.
Figure 5. Hierarchical clustering showing differential expres-
sion of tRNA synthetase genes. Heatmap of the linear fits from the
Limma analysis, showing tRNA synthetase genes primarily upregulated
in 5-Aza-CR treated T24 cells on day 2.
doi:10.1371/journal.pone.0012994.g005
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data show that an overlapping set of mRNAs was upregulated by
the two drugs, particularly 8 days after the initiation of treatment.
We observed that most genes upregulated by 5-Aza-CR also
become derepressed by 5-Aza-CdR at equitoxic doses. 5-Aza-CR
upregulates more genes on day 8 as compared to day 2 in both the
hematopoietic (HL-60) and the solid cancer (T24) cell line. Gene
reactivation seems to be progressive with time which may in part
explain the differences between our results and the previous studies
[26,30], in which gene expression was analyzed immediately after
72 hours and 48 hours of continuous treatment of different cell
lines.
The two FDA approved hypomethylating drugs are generally
thought to work by reactivating the transcription of TSGs that
have been downregulated by promoter hypermethylation in
cancer. Many in vitro studies have shown that both drugs induce
transcription of methylated TSGs through hypomethylation of the
gene promoters [31]. Quite surprisingly, our array data does not
show a significant upregulation of the methylated TSGs in either
of the two cell lines. So, although these genes may be upregulated
to levels detectable by highly sensitive PCR-based methods, they
are not part of the general dominant expression pattern induced by
these drugs. Mechanisms other than TSG derepression may
therefore also influence drug activity. Interestingly, a recent study
Table 1. Comparison of 5-Aza-CR (RNA & DNA Incorporation) with 5-Aza-CdR (DNA only).
Cell type Drug Immediate (Day 2) Heritable (Day 8)
HL60 Cells 5-Aza-CR XmRNA, q QmiRNAs XmRNA, qCTA, q QmiRNAs
5-Aza-CdR XmRNA, XCTA, q QmiRNAs XmRNA, qCTA, q QmiRNAs
T24 Cells 5-Aza-CR q QmRNA, YtRNA*, qYmiRNAs qmRNA, qCTA, q QmiRNAs
5-Aza-CdR qmRNA, qCTA, XmRNA, XCTA, q QmiRNAs
Up: X.X.q.q Down: Y,Y,Q,Q * Indirect evidence.
doi:10.1371/journal.pone.0012994.t001
Figure 6. miRNA expression after treatment with 5-Aza-CR and 5-Aza-CdR. Venn diagrams showing differentially expressed miRNAs in the
HL-60 AML cell line and the T24 bladder cancer cell line harvested and analyzed 1 and 7 days after treatment with equitoxic doses of 5-Aza-CR and 5-
Aza-CdR. The numbers in each area show miRNAs differentially expressed in treated relative to untreated cells. Upregulated miRNA are shown in
green, downregulated miRNAs in red.
doi:10.1371/journal.pone.0012994.g006
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and an HDAC inhibitor, also demonstrated that on day 15 after
treatment, only a few samples showed a significant upregulation of
TSGs, even when analyzed by PCR based methods, and TSG
upregulation could not be used as a measure of treatment efficacy
after 4 cycles [32]. Our data showed that the main common
feature of the two drugs was to induce a set of CTAs as has
previously been pointed out [33]. Some of these have CpG islands
in their gene promoters [34], and for the XAGE1D promoter
hypomethylation was associated with gene transcription. However,
a proportion of the upregulated CTAs did not have promoter
CpG islands. CTCFL/BORIS was one methylated CTA that
became significantly upregulated in both cell lines by both drugs.
CTCFL/BORIS is normally only expressed in germinal cells and
embryonic stem cells. When expressed in somatic cells it may
antagonize the activity of the epigenetic regulator CTCF, which is
ubiquitously expressed in all somatic cells. CTCF is a highly
conserved epigenetic controller that, depending on the cellular
context, may be involved in gene activation, repression, enhancer
blocking, insulation, genomic imprinting and long-range chromo-
somal interactions [35]. There is now evidence that CTCF is
involved in creating large inter- and/or intra chromosomal loops
that may protect larger chromosomal segments from transcription
[36]. The upregulation of CTCFL/BORIS in both cell lines (Fig. 3
and supplementary Fig. S4) suggests that many of the normal
CTCF activities may be interfered with during 5-Aza-CR and 5-
Aza-CdR treatment. Accordingly, gene segments that are
normally controlled by CTCF like some CTAs and the imprinted
H19 and DLK1 genes become upregulated. For the majority of
CTAs, upregulation coincided with upregulation of CTCFL/
BORIS by both treatment modalities, indicating that CTCFL/
BORIS may in part be responsible for the reactivation of CTAs as
have previously been described for the MAGE-A1 antigen [24,37].
Since CTAs are normally only expressed at immune privileged
sites like the testis, they are not subjected to self-tolerance.
Accordingly, CTAs may stimulate an immune response when
expressed in somatic cells, and may elicit coordinated humoral and
cell mediated immune responses [38].
A central difference between the two drugs is that only the ribo
analog exerts downregulation of RNA on day 2. All RNA species
are downregulated, but this appears to be distinctive for small
RNA species such as miRNAs and tRNAs. 5-Aza-CR seems to
have an immediate downregulatory effect on mRNAs, particularly
at higher doses (as used in the T24 cells) and on miRNAs at both
lower and higher doses in both cell lines. In T24 the
downregulation of miRNAs is dramatic with 46 miRNAs down
on day 2, and this is even more pronounced with higher doses
(data not shown). Since one miRNA may have several hundred
potential mRNA targets, downregulation of miRNAs may be
crucial to a large number of cellular functions [39].
These observations may be directly linked to the fact that 5-Aza-
CR treated T24 cells show significant upregulation of tRNA
synthetases on day 2, a change that is not seen by 5-Aza-CdR,
which show a general tendency towards tRNA synthetase
downregulation. These data are in line with the recent
observations by Hollenbach et al [30]. On day 8 both drugs in
both cell lines show tRNA synthetase downregulation. It was
recently shown that 5-Aza-CR, but not 5-Aza-CdR, directly
inhibits the RNA methyltransferase DNMT2, thereby causing
hypomethylation of tRNA, which may probably lead to its
destabilization [40]. Accordingly, it is tempting to speculate if the
incorporation into RNA and DNMT2 inactivation cause a
general, immediate decrease of certain RNA species. Furthermore,
it has been shown that the tRNAs produced during 5-Aza-CR
treatment are less efficient in protein synthesis [41]. In this
perspective upregulation of tRNA synthetases is most likely a
compensatory reaction against the immediate break down of
components involved in protein synthesis.
In general, our data show that in both cell lines there is a
prolonged induction time in 5-Aza-CR treated cells as compared
to 5-Aza-CdR treated cells. This may simply relate to the fact that
5-Aza-CR needs to be converted by ribo nucleotide reductase to
obtain maximum activity while 5-Aza-CdR does not. However,
other explanations of the prolonged induction time may relate to
mechanisms unrelated to DNA methylation such as induction of
transcription factors including CTCFL that secondarily upregu-
lates CTAs. Alternatively, the immediate downregulation of
tRNAs or CTA inhibitory miRNAs may be of importance.
The fact that the drugs have certain distinct immediate activities
on the transcriptome may suggest they can be used sequentially or
even in combination therapy. This is supported by a recent study
showing that 5-Aza-CdR resistant cell lines with mutations in the
DCK gene that encodes deoxycytidine kinase show 5-Aza-CR
sensitivity [42]. One clinical investigation of a small patient sample
has shown response to 5-Aza-CdR after failure to 5-Aza-CR [43].
However, the data in the present study are solely based on in
vitro observations and should be taken with precaution. Only
sequential measurements of the drug activities during the
treatment of patients will disclose which biological reactions are
active in vivo and crucial for drug efficacy. Thus, the true answer,
as to which drug is the most efficient, will require a carefully
designed large clinical trial that directly compares the two drugs
and their biological attributes.
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